{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:53:58Z","timestamp":1787734438090,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T00:00:00Z","timestamp":1735257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["Craiplo Grant 2020-3623"],"award-info":[{"award-number":["Craiplo Grant 2020-3623"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SMA Europe Grant","award":["22739"],"award-info":[{"award-number":["22739"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-024-05550-3","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T02:53:59Z","timestamp":1735268039000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting STMN2 for neuroprotection and neuromuscular recovery in Spinal Muscular Atrophy: evidence from in vitro and in vivo SMA models"],"prefix":"10.1007","volume":"82","author":[{"given":"Elisa","family":"Pagliari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Taiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Quetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Bertolasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samanta","family":"Oldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Melzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Nizzardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7677-0330","authenticated-orcid":false,"given":"Federica","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,27]]},"reference":[{"key":"5550_CR1","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/S0092-8674(00)81632-3","volume":"95","author":"L Pellizzoni","year":"1998","unstructured":"Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G (1998) A novel function for SMN, the spinal muscular atrophy Disease Gene product, in Pre-mRNA splicing. Cell 95:615\u2013624. https:\/\/doi.org\/10.1016\/S0092-8674(00)81632-3","journal-title":"Cell"},{"key":"5550_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrneurol.2015.77","volume":"11","author":"I Faravelli","year":"2015","unstructured":"Faravelli I, Nizzardo M, Comi GP, Corti S (2015) Spinal muscular atrophy\u2014recent therapeutic advances for an old challenge. Nat Rev Neurol 11:351\u2013359. https:\/\/doi.org\/10.1038\/nrneurol.2015.77","journal-title":"Nat Rev Neurol"},{"key":"5550_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/jmg.15.6.409","volume":"15","author":"J Pearn","year":"1978","unstructured":"Pearn J (1978) Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 15:409\u2013413. https:\/\/doi.org\/10.1136\/jmg.15.6.409","journal-title":"J Med Genet"},{"key":"5550_CR4","volume-title":"Spinal muscular atrophy: disease mechanisms and therapy","author":"CJ Sumner","year":"2017","unstructured":"Sumner CJ, Paushkin S, Ko C-P (2017) Spinal muscular atrophy: disease mechanisms and therapy. Elsevier\/Academic, Amsterdam"},{"key":"5550_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E (2011) Spinal muscular atrophy. Orphanet J Rare Dis 6:71. https:\/\/doi.org\/10.1186\/1750-1172-6-71","journal-title":"Orphanet J Rare Dis"},{"key":"5550_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0959-437X(02)00301-5","volume":"12","author":"T Frugier","year":"2002","unstructured":"Frugier T, Nicole S, Cifuentes-Diaz C, Melki J (2002) The molecular bases of spinal muscular atrophy. Curr Opin Genet Dev 12:294\u2013298. https:\/\/doi.org\/10.1016\/S0959-437X(02)00301-5","journal-title":"Curr Opin Genet Dev"},{"key":"5550_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, B\u00fcrglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155\u2013165. https:\/\/doi.org\/10.1016\/0092-8674(95)90460-3","journal-title":"Cell"},{"key":"5550_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1586\/14737159.4.1.15","volume":"4","author":"S Ogino","year":"2004","unstructured":"Ogino S, Wilson RB (2004) Spinal muscular atrophy: molecular genetics and diagnostics. Expert Rev Mol Diagn 4:15\u201329. https:\/\/doi.org\/10.1586\/14737159.4.1.15","journal-title":"Expert Rev Mol Diagn"},{"key":"5550_CR9","doi-asserted-by":"publisher","first-page":"13743","DOI":"10.3390\/ijms241813743","volume":"24","author":"AS Ponomarev","year":"2023","unstructured":"Ponomarev AS, Chulpanova DS, Yanygina LM et al (2023) Emerging Gene Therapy approaches in the management of spinal muscular atrophy (SMA): an overview of clinical trials and patent Landscape. IJMS 24:13743. https:\/\/doi.org\/10.3390\/ijms241813743","journal-title":"IJMS"},{"key":"5550_CR10","doi-asserted-by":"publisher","first-page":"E4604","DOI":"10.1073\/pnas.1800260115","volume":"115","author":"J Wang","year":"2018","unstructured":"Wang J, Schultz PG, Johnson KA (2018) Mechanistic studies of a small-molecule modulator of SMN2 splicing. Proc Natl Acad Sci U S A 115:E4604\u2013E4612. https:\/\/doi.org\/10.1073\/pnas.1800260115","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5550_CR11","doi-asserted-by":"publisher","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","volume":"61","author":"H Ratni","year":"2018","unstructured":"Ratni H, Ebeling M, Baird J et al (2018) Discovery of Risdiplam, a selective survival of Motor Neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem 61:6501\u20136517. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00741","journal-title":"J Med Chem"},{"key":"5550_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2102047","volume":"385","author":"BT Darras","year":"2021","unstructured":"Darras BT, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M et al (2021) Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls. N Engl J Med 385:427\u2013435. https:\/\/doi.org\/10.1056\/NEJMoa2102047","journal-title":"N Engl J Med"},{"key":"5550_CR13","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1111\/ene.15499","volume":"30","author":"E Mercuri","year":"2023","unstructured":"Mercuri E, Baranello G, Boespflug-Tanguy O et al (2023) Risdiplam in types 2 and 3 spinal muscular atrophy: a randomised, placebo-controlled, dose-finding trial followed by 24 months of treatment. Eur J Neurol 30:1945\u20131956. https:\/\/doi.org\/10.1111\/ene.15499","journal-title":"Eur J Neurol"},{"key":"5550_CR14","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus Sham Control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723\u20131732. https:\/\/doi.org\/10.1056\/NEJMoa1702752","journal-title":"N Engl J Med"},{"key":"5550_CR15","doi-asserted-by":"publisher","unstructured":"Van Der Wadman RI, Bosboom WM et al (2019) Drug treatment for spinal muscular atrophy type I. https:\/\/doi.org\/10.1002\/14651858.CD006281.pub5. Cochrane Database of Systematic Reviews","DOI":"10.1002\/14651858.CD006281.pub5"},{"key":"5550_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","volume":"79","author":"SM Hoy","year":"2019","unstructured":"Hoy SM (2019) Onasemnogene Abeparvovec: First Global approval. Drugs 79:1255\u20131262. https:\/\/doi.org\/10.1007\/s40265-019-01162-5","journal-title":"Drugs"},{"key":"5550_CR17","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41593-021-00827-3","volume":"24","author":"M Van Alstyne","year":"2021","unstructured":"Van Alstyne M, Tattoli I, Delestr\u00e9e N et al (2021) Gain of toxic function by long-term AAV9-mediated SMN overexpression in the sensorimotor circuit. Nat Neurosci 24:930\u2013940. https:\/\/doi.org\/10.1038\/s41593-021-00827-3","journal-title":"Nat Neurosci"},{"key":"5550_CR18","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.xcrm.2021.100346","volume":"2","author":"H Chaytow","year":"2021","unstructured":"Chaytow H, Faller KME, Huang Y-T, Gillingwater TH (2021) Spinal muscular atrophy: from approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2:100346. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100346","journal-title":"Cell Rep Med"},{"key":"5550_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth B (2021) Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci 44:306\u2013322. https:\/\/doi.org\/10.1016\/j.tins.2020.11.009","journal-title":"Trends Neurosci"},{"key":"5550_CR20","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ et al (2019) Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the phase 2 NURTURE study. Neuromuscul Disord 29:842\u2013856. https:\/\/doi.org\/10.1016\/j.nmd.2019.09.007","journal-title":"Neuromuscul Disord"},{"key":"5550_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713\u20131722. https:\/\/doi.org\/10.1056\/NEJMoa1706198","journal-title":"N Engl J Med"},{"key":"5550_CR22","doi-asserted-by":"publisher","first-page":"5948","DOI":"10.1093\/nar\/gkad259","volume":"51","author":"EW Ottesen","year":"2023","unstructured":"Ottesen EW, Singh NN, Luo D et al (2023) Diverse targets of SMN2 -directed splicing-modulating small molecule therapeutics for spinal muscular atrophy. Nucleic Acids Res 51:5948\u20135980. https:\/\/doi.org\/10.1093\/nar\/gkad259","journal-title":"Nucleic Acids Res"},{"key":"5550_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1242\/dmm.030148","volume":"10","author":"M Bowerman","year":"2017","unstructured":"Bowerman M, Becker CG, Y\u00e1\u00f1ez-Mu\u00f1oz RJ et al (2017) Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Dis Model Mech 10:943\u2013954. https:\/\/doi.org\/10.1242\/dmm.030148","journal-title":"Dis Model Mech"},{"key":"5550_CR24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1126\/science.1155085","volume":"320","author":"GE Oprea","year":"2008","unstructured":"Oprea GE, Kr\u00f6ber S, McWhorter ML et al (2008) Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 320:524\u2013527. https:\/\/doi.org\/10.1126\/science.1155085","journal-title":"Science"},{"key":"5550_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ajhg.2017.01.005","volume":"100","author":"M Riessland","year":"2017","unstructured":"Riessland M, Kaczmarek A, Schneider S et al (2017) Neurocalcin Delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. Am J Hum Genet 100:297\u2013315. https:\/\/doi.org\/10.1016\/j.ajhg.2017.01.005","journal-title":"Am J Hum Genet"},{"key":"5550_CR26","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1093\/brain\/awy167","volume":"141","author":"E Janzen","year":"2018","unstructured":"Janzen E, Mendoza-Ferreira N, Hosseinibarkooie S et al (2018) CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis. Brain 141:2343\u20132361. https:\/\/doi.org\/10.1093\/brain\/awy167","journal-title":"Brain"},{"key":"5550_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/brain\/awy330","volume":"142","author":"F Rizzo","year":"2019","unstructured":"Rizzo F, Nizzardo M, Vashisht S et al (2019) Key role of SMN\/SYNCRIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons. Brain 142:276\u2013294. https:\/\/doi.org\/10.1093\/brain\/awy330","journal-title":"Brain"},{"key":"5550_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pneurobio.2014.09.002","volume":"126","author":"S Chauvin","year":"2015","unstructured":"Chauvin S, Sobel A (2015) Neuronal stathmins: a family of phosphoproteins cooperating for neuronal development, plasticity and regeneration. Prog Neurobiol 126:1\u201318. https:\/\/doi.org\/10.1016\/j.pneurobio.2014.09.002","journal-title":"Prog Neurobiol"},{"key":"5550_CR29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0092-8674(85)90122-9","volume":"42","author":"DJ Anderson","year":"1985","unstructured":"Anderson DJ, Axel R (1985) Molecular probes for the development and plasticity of neural crest derivatives. Cell 42:649\u2013662. https:\/\/doi.org\/10.1016\/0092-8674(85)90122-9","journal-title":"Cell"},{"key":"5550_CR30","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/j.1432-1033.1997.t01-2-00794.x","volume":"248","author":"S Ozon","year":"1997","unstructured":"Ozon S, Maucuer A, Sobel A (1997) The Stathmin Family: Molecular and Biological characterization of Novel mammalian proteins expressed in the nervous system. Eur J Biochem 248:794\u2013806. https:\/\/doi.org\/10.1111\/j.1432-1033.1997.t01-2-00794.x","journal-title":"Eur J Biochem"},{"key":"5550_CR31","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1073\/pnas.94.2.741","volume":"94","author":"BM Riederer","year":"1997","unstructured":"Riederer BM, Pellier V, Antonsson B et al (1997) Regulation of microtubule dynamics by the neuronal growth-associated protein SCG10. Proc Natl Acad Sci USA 94:741\u2013745. https:\/\/doi.org\/10.1073\/pnas.94.2.741","journal-title":"Proc Natl Acad Sci USA"},{"key":"5550_CR32","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8","volume":"50","author":"G Di Paolo","year":"1997","unstructured":"Di Paolo G, Lutjens R, Osen-Sand A et al (1997) Differential distribution of stathmin and SCG10 in developing neurons in culture. J Neurosci Res 50:1000\u20131009.","journal-title":"J Neurosci Res"},{"key":"5550_CR33","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/biomedicines10030711","volume":"10","author":"D Gagliardi","year":"2022","unstructured":"Gagliardi D, Pagliari E, Meneri M et al (2022) Stathmins and Motor Neuron diseases: pathophysiology and therapeutic targets. Biomedicines 10:711. https:\/\/doi.org\/10.3390\/biomedicines10030711","journal-title":"Biomedicines"},{"key":"5550_CR34","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1172\/JCI139741","volume":"130","author":"M Prudencio","year":"2020","unstructured":"Prudencio M, Humphrey J, Pickles S et al (2020) Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J Clin Invest 130:6080\u20136092. https:\/\/doi.org\/10.1172\/JCI139741","journal-title":"J Clin Invest"},{"key":"5550_CR35","doi-asserted-by":"publisher","first-page":"5234","DOI":"10.1038\/s41467-019-13144-y","volume":"10","author":"Q Wang","year":"2019","unstructured":"Wang Q, Zhang Y, Wang M et al (2019) The landscape of multiscale transcriptomic networks and key regulators in Parkinson\u2019s disease. Nat Commun 10:5234. https:\/\/doi.org\/10.1038\/s41467-019-13144-y","journal-title":"Nat Commun"},{"key":"5550_CR36","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41593-018-0300-4","volume":"22","author":"JR Klim","year":"2019","unstructured":"Klim JR, Williams LA, Limone F et al (2019) ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci 22:167\u2013179. https:\/\/doi.org\/10.1038\/s41593-018-0300-4","journal-title":"Nat Neurosci"},{"key":"5550_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41593-018-0293-z","volume":"22","author":"Z Melamed","year":"2019","unstructured":"Melamed Z, L\u00f3pez-Erauskin J, Baughn MW et al (2019) Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci 22:180\u2013190. https:\/\/doi.org\/10.1038\/s41593-018-0293-z","journal-title":"Nat Neurosci"},{"key":"5550_CR38","doi-asserted-by":"publisher","unstructured":"Corti S, Nizzardo M, Simone C et al (2012) Genetic correction of Human Induced Pluripotent Stem cells from patients with spinal muscular atrophy. Sci Transl Med 4. https:\/\/doi.org\/10.1126\/scitranslmed.3004108","DOI":"10.1126\/scitranslmed.3004108"},{"key":"5550_CR39","doi-asserted-by":"publisher","first-page":"111001","DOI":"10.1016\/j.celrep.2022.111001","volume":"39","author":"KL Krus","year":"2022","unstructured":"Krus KL, Strickland A, Yamada Y et al (2022) Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Cell Rep 39:111001. https:\/\/doi.org\/10.1016\/j.celrep.2022.111001","journal-title":"Cell Rep"},{"key":"5550_CR40","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00401-020-02133-x","volume":"139","author":"M Nizzardo","year":"2020","unstructured":"Nizzardo M, Taiana M, Rizzo F et al (2020) Synaptotagmin 13 is neuroprotective across motor neuron diseases. Acta Neuropathol 139:837\u2013853. https:\/\/doi.org\/10.1007\/s00401-020-02133-x","journal-title":"Acta Neuropathol"},{"key":"5550_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nbt.3049","volume":"33","author":"Y Maury","year":"2015","unstructured":"Maury Y, C\u00f4me J, Piskorowski RA et al (2015) Combinatorial analysis of developmental cues efficiently converts human pluripotent stem cells into multiple neuronal subtypes. Nat Biotechnol 33:89\u201396. https:\/\/doi.org\/10.1038\/nbt.3049","journal-title":"Nat Biotechnol"},{"key":"5550_CR42","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/hmg\/ddi078","volume":"14","author":"TT Le","year":"2005","unstructured":"Le TT, Pham LT, Butchbach MER et al (2005) SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet 14:845\u2013857. https:\/\/doi.org\/10.1093\/hmg\/ddi078","journal-title":"Hum Mol Genet"},{"key":"5550_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.nbd.2007.04.009","volume":"27","author":"MER Butchbach","year":"2007","unstructured":"Butchbach MER, Edwards JD, Burghes AHM (2007) Abnormal motor phenotype in the SMN\u22067 mouse model of spinal muscular atrophy. Neurobiol Dis 27:207\u2013219. https:\/\/doi.org\/10.1016\/j.nbd.2007.04.009","journal-title":"Neurobiol Dis"},{"key":"5550_CR44","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.clinthera.2014.02.004","volume":"36","author":"M Nizzardo","year":"2014","unstructured":"Nizzardo M, Simone C, Salani S et al (2014) Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy \u22067 mouse model phenotype. Clin Ther 36:340\u2013356e5. https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.004","journal-title":"Clin Ther"},{"key":"5550_CR45","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1083\/jcb.200511055","volume":"173","author":"T Tararuk","year":"2006","unstructured":"Tararuk T, \u00d6stman N, Li W et al (2006) JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length. J Cell Biol 173:265\u2013277. https:\/\/doi.org\/10.1083\/jcb.200511055","journal-title":"J Cell Biol"},{"key":"5550_CR46","doi-asserted-by":"publisher","first-page":"13681","DOI":"10.1073\/pnas.251194298","volume":"98","author":"BL Bennett","year":"2001","unstructured":"Bennett BL, Sasaki DT, Murray BW et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci U S A 98:13681\u201313686. https:\/\/doi.org\/10.1073\/pnas.251194298","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5550_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/hmg\/ddr453","volume":"21","author":"KKY Ling","year":"2012","unstructured":"Ling KKY, Gibbs RM, Feng Z, Ko C-P (2012) Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy. Hum Mol Genet 21:185\u2013195. https:\/\/doi.org\/10.1093\/hmg\/ddr453","journal-title":"Hum Mol Genet"},{"key":"5550_CR48","doi-asserted-by":"publisher","first-page":"8691","DOI":"10.1523\/JNEUROSCI.0417-15.2015","volume":"35","author":"S Tisdale","year":"2015","unstructured":"Tisdale S, Pellizzoni L (2015) Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci 35:8691\u20138700. https:\/\/doi.org\/10.1523\/JNEUROSCI.0417-15.2015","journal-title":"J Neurosci"},{"key":"5550_CR49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fnana.2016.00006","volume":"10","author":"M Boido","year":"2016","unstructured":"Boido M, Vercelli A (2016) Neuromuscular junctions as Key contributors and therapeutic targets in spinal muscular atrophy. Front Neuroanat 10:6. https:\/\/doi.org\/10.3389\/fnana.2016.00006","journal-title":"Front Neuroanat"},{"key":"5550_CR50","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1093\/hmg\/ddn156","volume":"17","author":"S Kariya","year":"2008","unstructured":"Kariya S, Park G-H, Maeno-Hikichi Y et al (2008) Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 17:2552\u20132569. https:\/\/doi.org\/10.1093\/hmg\/ddn156","journal-title":"Hum Mol Genet"},{"key":"5550_CR51","doi-asserted-by":"publisher","first-page":"e82654","DOI":"10.1371\/journal.pone.0082654","volume":"8","author":"P d\u2019Errico","year":"2013","unstructured":"d\u2019Errico P, Boido M, Piras A et al (2013) Selective vulnerability of spinal and cortical motor neuron subpopulations in delta7 SMA mice. PLoS ONE 8:e82654. https:\/\/doi.org\/10.1371\/journal.pone.0082654","journal-title":"PLoS ONE"},{"key":"5550_CR52","doi-asserted-by":"publisher","first-page":"15026","DOI":"10.1523\/JNEUROSCI.2024-11.2011","volume":"31","author":"ER Graf","year":"2011","unstructured":"Graf ER, Heerssen HM, Wright CM et al (2011) Stathmin is required for stability of the Drosophila neuromuscular junction. J Neurosci 31:15026\u201315034. https:\/\/doi.org\/10.1523\/JNEUROSCI.2024-11.2011","journal-title":"J Neurosci"},{"key":"5550_CR53","doi-asserted-by":"publisher","unstructured":"Shin JE, Miller BR, Babetto E et al (2012) SCG10 is a JNK target in the axonal degeneration pathway. Proc Natl Acad Sci USA 109. https:\/\/doi.org\/10.1073\/pnas.1216204109","DOI":"10.1073\/pnas.1216204109"},{"key":"5550_CR54","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.3390\/cells8121576","volume":"8","author":"R Schellino","year":"2019","unstructured":"Schellino R, Boido M, Vercelli A (2019) JNK Signaling Pathway involvement in spinal cord Neuron Development and Death. Cells 8:1576. https:\/\/doi.org\/10.3390\/cells8121576","journal-title":"Cells"},{"key":"5550_CR55","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1093\/hmg\/ddv401","volume":"24","author":"NK Genabai","year":"2015","unstructured":"Genabai NK, Ahmad S, Zhang Z et al (2015) Genetic inhibition of JNK3 ameliorates spinal muscular atrophy. Hum Mol Genet 24:6986\u20137004. https:\/\/doi.org\/10.1093\/hmg\/ddv401","journal-title":"Hum Mol Genet"},{"key":"5550_CR56","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1126\/science.1250127","volume":"345","author":"NA Naryshkin","year":"2014","unstructured":"Naryshkin NA, Weetall M, Dakka A et al (2014) Motor neuron disease. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science 345:688\u2013693. https:\/\/doi.org\/10.1126\/science.1250127","journal-title":"Science"},{"key":"5550_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nature10485","volume":"478","author":"Y Hua","year":"2011","unstructured":"Hua Y, Sahashi K, Rigo F et al (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478:123\u2013126. https:\/\/doi.org\/10.1038\/nature10485","journal-title":"Nature"},{"key":"5550_CR58","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajhg.2016.07.014","volume":"99","author":"S Hosseinibarkooie","year":"2016","unstructured":"Hosseinibarkooie S, Peters M, Torres-Benito L et al (2016) The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. Am J Hum Genet 99:647\u2013665. https:\/\/doi.org\/10.1016\/j.ajhg.2016.07.014","journal-title":"Am J Hum Genet"},{"key":"5550_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JND-190424","volume":"7","author":"DC Schorling","year":"2020","unstructured":"Schorling DC, Pechmann A, Kirschner J (2020) Advances in treatment of spinal muscular atrophy - new phenotypes, New challenges, New implications for Care. J Neuromuscul Dis 7:1\u201313. https:\/\/doi.org\/10.3233\/JND-190424","journal-title":"J Neuromuscul Dis"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05550-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-024-05550-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-024-05550-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T03:07:15Z","timestamp":1735268835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-024-05550-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,27]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5550"],"URL":"https:\/\/doi.org\/10.1007\/s00018-024-05550-3","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,27]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments strictly follow the guidelines of the Italian Ministry of Health in compliance with U.S. National Institutes of Health Guide for the Care and Use of Laboratory Animals (718\/2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the authors have approved and agreed to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29"}}